United States

Showing 261-270 of 354 grants

Title	Institution	Researcher	Program	Duration	Total Award Amount
REGULATORY ROLE OF CADM1 DURING AUTOIMMUNE DIABETES	Johns Hopkins University	Matthew Poy	Cures	01-December-2024 to 30-November-2027	$900,000.00
Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth	Johns Hopkins University	Risa Wolf	Improving Lives	01-January-2023 to 31-December-2026	$637,547.20
Studies of Promising Functional Endpoints in Eyes of Patients with Diabetes (Protocols AR and AS )	Jaeb Center for Health Research	Adam Glassman	Improving Lives	01-May-2026 to 30-April-2030	$1,035,583.00
Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening	Jaeb Center for Health Research	Adam Glassman	Improving Lives	01-February-2021 to 31-August-2026	$750,000.00
JDRF T1D Coordinating Center	Jaeb Center for Health Research	Judy Sibayan	Transportfolio	01-August-2019 to 31-August-2027	$2,914,531.01
Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes	iTolerance, Inc.	Camillo Ricordi	Cures	01-June-2022 to 31-March-2027	$850,000.00
Advancing T1D Detection and Care Through AI	IQVIA, Inc.	Nadejda Leavitt	Cures	01-February-2025 to 31-October-2026	$345,083.00
Adult T1D Detection at Geisinger	IQVIA, Inc.	Nadejda Leavitt	Cures	01-July-2023 to 30-June-2027	$1,033,123.00
Clinical Translation of T-1123, an Ultra-rapid, Concentrated, Temperature stable Novel Insulin Analog	Invictus Therapeutics, LLC	Robyn Day	Improving Lives	15-October-2025 to 31-May-2027	$1,437,112.00
Exploiting SDF2L1 to protect against beta cell death and dysfunction in T1D	Indiana Biosciences Research Institute	Michael Kalwat	Cures	01-December-2024 to 30-November-2027	$748,169.00